|
gptkbp:instanceOf
|
gptkb:drug
aptamer
|
|
gptkbp:administeredBy
|
intravitreal injection
|
|
gptkbp:approvedBy
|
gptkb:FDA
2004
|
|
gptkbp:ATCCode
|
S01LA03
|
|
gptkbp:brand
|
gptkb:Macugen
|
|
gptkbp:CASNumber
|
320345-39-7
|
|
gptkbp:contraindication
|
ocular infection
hypersensitivity to pegaptanib
|
|
gptkbp:developedBy
|
gptkb:Pfizer
gptkb:Eyetech_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
10 days (in vitreous)
|
|
gptkbp:hasMolecularFormula
|
C294H375F2N119Na40O190P40
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pegaptanib
|
|
gptkbp:indication
|
neovascular (wet) AMD
|
|
gptkbp:isA
|
anti-VEGF therapy
|
|
gptkbp:KEGGID
|
D04733
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
VEGF inhibitor
|
|
gptkbp:molecularWeight
|
50 kDa
|
|
gptkbp:origin
|
synthetic
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
16130129
CHEMBL1201587
DB00082
|
|
gptkbp:routeOfAdministration
|
intravitreal
|
|
gptkbp:sideEffect
|
inflammation
eye pain
increased intraocular pressure
retinal detachment
floaters
|
|
gptkbp:structureType
|
RNA aptamer
|
|
gptkbp:target
|
gptkb:VEGF165
|
|
gptkbp:UNII
|
Q1U8A8V42J
|
|
gptkbp:usedFor
|
age-related macular degeneration
|
|
gptkbp:bfsParent
|
gptkb:Aptamers
|
|
gptkbp:bfsLayer
|
7
|